AR074770A1 - Producto que contiene nicotina - Google Patents
Producto que contiene nicotinaInfo
- Publication number
- AR074770A1 AR074770A1 ARP090104938A ARP090104938A AR074770A1 AR 074770 A1 AR074770 A1 AR 074770A1 AR P090104938 A ARP090104938 A AR P090104938A AR P090104938 A ARP090104938 A AR P090104938A AR 074770 A1 AR074770 A1 AR 074770A1
- Authority
- AR
- Argentina
- Prior art keywords
- nicotine
- product
- pharmaceutically acceptable
- preparation
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a un producto que contiene nicotina que comprende un sustrato polimérico farmacéuticamente aceptable, el cual es capaz de unirse a cationes, nicotina o un derivado de nicotina farmacéuticamente aceptable, y cationes inorgánicos farmacéuticamente aceptables. También se refiere a un método para la preparación de dicho producto que contiene nicotina y a su uso para la preparación de un producto farmacéutico. Reivindicación 2: Producto que contiene nicotina de acuerdo con la reivindicación 1, caracterizado en que el sustrato polimérico farmacéuticamente aceptable se selecciona del grupo que consiste en resinas de intercambio catiónico y polisacáridos. Reivindicación 6: Producto que contiene nicotina de acuerdo con una de las reivindicaciones 1 a 5, caracterizado en que comprende menos de 20% en peso de nicotina o el derivado de nicotina farmacéuticamente aceptable, preferentemente 8-18% en peso, más preferentemente 10-15% en peso. Reivindicación 8: Producto que contiene nicotina de acuerdo con una de las reivindicaciones 1 a 7, caracterizado en que el catión inorgánico farmacéuticamente aceptable se selecciona del grupo que consiste en Li+, K+, Na+, Mg2+, Ca2+, Fe2+, Zn2+ y mezclas de los mismos. Reivindicación 14: Uso de un producto que contiene nicotina de acuerdo con una de las reivindicaciones 1 a 9 para la preparación de un producto farmacéutico que contiene nicotina destinado para la administración oral. Reivindicación 15: Uso de un producto que contiene nicotina de acuerdo con una de las reivindicaciones 1 a 9 para la preparación de un producto farmacéutico que contiene nicotina destinado para la administración transdérmica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08022123A EP2198865B1 (en) | 2008-12-19 | 2008-12-19 | Nicotine-containing product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074770A1 true AR074770A1 (es) | 2011-02-09 |
Family
ID=40602533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104938A AR074770A1 (es) | 2008-12-19 | 2009-12-17 | Producto que contiene nicotina |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9585967B2 (es) |
| EP (2) | EP2392331A1 (es) |
| AR (1) | AR074770A1 (es) |
| AT (1) | ATE533487T1 (es) |
| AU (1) | AU2009328589B2 (es) |
| CA (1) | CA2734403C (es) |
| DK (1) | DK2198865T3 (es) |
| ES (1) | ES2377673T3 (es) |
| HR (1) | HRP20110954T1 (es) |
| MX (1) | MX2011003942A (es) |
| NZ (1) | NZ591209A (es) |
| PL (1) | PL2198865T3 (es) |
| PT (1) | PT2198865E (es) |
| SI (1) | SI2198865T1 (es) |
| UY (1) | UY32337A (es) |
| WO (1) | WO2010069507A1 (es) |
| ZA (1) | ZA201101124B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11911375B2 (en) * | 2020-11-16 | 2024-02-27 | Fertin Pharma A/S | Solid oral nicotine formulation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3901248A (en) | 1970-07-22 | 1975-08-26 | Leo Ab | Chewable smoking substitute composition |
| GB1332503A (en) * | 1970-10-15 | 1973-10-03 | British American Tobacco Co | Smoking compositions |
| US3845217A (en) * | 1972-11-16 | 1974-10-29 | Helsingborg L Ab | Buffered smoking substitute compositions |
| IT1104351B (it) * | 1978-06-14 | 1985-10-21 | Muzzarelli Riccardo | Il complesso glucano chitosano il metodo della sua produzione a partire da muffe funghi e lieviti e i suoi usi |
| GB9310412D0 (en) | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
| GB2385288A (en) | 2002-01-18 | 2003-08-20 | Advanced Phytonics Ltd | Preparing a resinate. |
| US6586449B1 (en) | 2002-05-28 | 2003-07-01 | Cambrex Charles City, Inc. | Nicotine-containing, controlled release composition and method |
| US20050123502A1 (en) * | 2003-10-07 | 2005-06-09 | Chan Shing Y. | Nicotine containing oral compositions |
| ATE439839T1 (de) | 2003-12-02 | 2009-09-15 | Fertin Pharma As | Nikotin-abgabeprodukt und herstellungsverfahren |
| US20070269386A1 (en) * | 2006-05-16 | 2007-11-22 | Per Steen | New product and use and manufacture thereof |
| US20070269492A1 (en) * | 2006-05-16 | 2007-11-22 | Per Steen | New product and use and manufacture thereof |
| ES2401912T3 (es) * | 2008-09-17 | 2013-04-25 | Siegfried Ltd. | Granulado que contiene nicotina |
-
2008
- 2008-12-19 SI SI200830503T patent/SI2198865T1/sl unknown
- 2008-12-19 DK DK08022123.7T patent/DK2198865T3/da active
- 2008-12-19 ES ES08022123T patent/ES2377673T3/es active Active
- 2008-12-19 PT PT08022123T patent/PT2198865E/pt unknown
- 2008-12-19 EP EP11007015A patent/EP2392331A1/en not_active Withdrawn
- 2008-12-19 EP EP08022123A patent/EP2198865B1/en active Active
- 2008-12-19 AT AT08022123T patent/ATE533487T1/de active
- 2008-12-19 PL PL08022123T patent/PL2198865T3/pl unknown
-
2009
- 2009-12-10 US US13/058,778 patent/US9585967B2/en active Active
- 2009-12-10 NZ NZ591209A patent/NZ591209A/xx not_active IP Right Cessation
- 2009-12-10 MX MX2011003942A patent/MX2011003942A/es active IP Right Grant
- 2009-12-10 AU AU2009328589A patent/AU2009328589B2/en not_active Ceased
- 2009-12-10 WO PCT/EP2009/008822 patent/WO2010069507A1/en active Application Filing
- 2009-12-10 CA CA2734403A patent/CA2734403C/en active Active
- 2009-12-17 UY UY0001032337A patent/UY32337A/es not_active Application Discontinuation
- 2009-12-17 AR ARP090104938A patent/AR074770A1/es unknown
-
2011
- 2011-02-11 ZA ZA2011/01124A patent/ZA201101124B/en unknown
- 2011-12-19 HR HR20110954T patent/HRP20110954T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2198865T3 (da) | 2012-01-16 |
| ATE533487T1 (de) | 2011-12-15 |
| ES2377673T3 (es) | 2012-03-29 |
| CA2734403A1 (en) | 2010-06-24 |
| PL2198865T3 (pl) | 2012-04-30 |
| CA2734403C (en) | 2013-05-14 |
| AU2009328589A1 (en) | 2010-06-24 |
| EP2198865B1 (en) | 2011-11-16 |
| AU2009328589B2 (en) | 2012-12-06 |
| US20110207782A1 (en) | 2011-08-25 |
| EP2198865A1 (en) | 2010-06-23 |
| SI2198865T1 (sl) | 2012-02-29 |
| NZ591209A (en) | 2012-11-30 |
| EP2392331A1 (en) | 2011-12-07 |
| MX2011003942A (es) | 2011-05-19 |
| HRP20110954T1 (hr) | 2012-01-31 |
| PT2198865E (pt) | 2012-02-07 |
| ZA201101124B (en) | 2012-05-30 |
| UY32337A (es) | 2010-07-30 |
| WO2010069507A1 (en) | 2010-06-24 |
| US9585967B2 (en) | 2017-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2009000498A1 (es) | Compuestos derivados de benzo [f][1,7]naftiridin sustituidos, moduladores de receptor toll; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedad infecciosa, inflamatoria, dermatologica, respiratoria o inmune. | |
| AR073604A1 (es) | Granulado que contiene nicotina | |
| PE20080765A1 (es) | Formas de dosificacion farmaceutica | |
| UA105033C2 (uk) | Фармацевтична композиція, що включає глюкопіранозилзаміщене похідне бензолу, фармацевтична дозована форма, що містить зазначене похідне, їх застосування для лікування метаболічного порушення | |
| AR060932A1 (es) | Producto y su uso y elaboracion | |
| AR078846A1 (es) | Composicion para el tratamiento de la enfermedad de alzheimer | |
| AR093340A1 (es) | Composiciones farmaceuticas para el tratamiento de enfermedades mediadas por cftr, granulo, comprimido, proceso continuo para la preparacion de un comprimido | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| AR050717A1 (es) | Composiciones farmaceuticas | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| AR086652A1 (es) | Metodos de tratamiento, composiciones farmaceuticas y usos de los mismos | |
| BR112014014341A2 (pt) | Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica | |
| AR056873A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas | |
| CO6321225A2 (es) | Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico | |
| AR066585A1 (es) | Nuevo producto y su uso y fabricacion | |
| BRPI0609719B8 (pt) | derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2 | |
| CO6400185A2 (es) | Formas de dosificación sólida de bendamustina | |
| BR112012012906A2 (pt) | triazolopiridinas | |
| BR112013028776A2 (pt) | kit, e, uso de uma composição farmacêutica ou nutracêutica | |
| BRPI0806863B8 (pt) | uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv | |
| ECSP14013275A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
| BR112017026287A2 (pt) | composições de hidroxipropil beta-ciclodextrina e métodos | |
| AR083150A1 (es) | Composiciones farmaceuticas que comprenden hidromorfona y naloxona | |
| CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
| BRPI0806400A8 (pt) | composto, composição farmacêutica, produtos, usos de pelo menos um composto, método in vitro, kit, ligantes e processo de preparação de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |